RE: Molecular Clinical Diagnostics qPCR portfolio12 Apr 2023 18:47
Thx Larry , I'm still trying to get to grips with yesterday's home page New York Times, showing our q16 and Q32.
Been onto the diagnostic companies site , listened to a few hours of vids on cotton and cannabis and molecular tagging , all potentially huge business , but am currently failing to comprehend exactly where the use of our instruments come into play. They obviously do as photographed.
https://twitter.com/KilkennyTed/status/1645779192154411008?t=QSXQZZ-V6I5TpDCL4I8gkQ&s=19
So bloody frustrating , they could tell us sooo much but elect to tell us a big fat juicy zero.
Take that brochure , it's a year old , bet there is a load more 'stuff' they've developed since then.
No wonder we are all more than a trite peed off!!!
Re your post the other day about Tata using our assays, I consider myself quite well informed about Ncyt , as much as I can be , with very little inf from company and I just assumed not ours , although I could see so many similarities. I reached that conclusion because I could see nothing in any sales figures to reflect we were selling bucket loads of tests to them.
Perhaps we will get a nice surprise , best I hurry up and finish what I'm doing up a ladder or I'll fall off in shock !! :)